For the Inventor, By the Inventor

Enter assignee name

Centaurus Biopharma Co., Ltd.

USPTO Granted Patents = 33

CIPO Patents = 2

EPO Patents = 26

Forward Citations = 53

Loading Chart...

Loading Chart...

105 inventors (with patents filed for the assignee):

Yongxin Han (17 out of 21 patents)

Yong Peng (14 out of 26 patents)

Yuandong Hu (14 out of 15 patents)

4. Hong Luo (13 out of 17 patents)

5. Dengming Xiao (12 out of 14 patents)

6. Xiquan Zhang (10 out of 43 patents)

7. Xijie Liu (9 out of 9 patents)

8. Li Zhu (8 out of 36 patents)

9. Fei Liu (8 out of 17 patents)

10. Hongjiang Xu (8 out of 28 patents)

11. Hui Zhang (7 out of 116 patents)

12. Na Zhao (6 out of 26 patents)

13. Rui Zhao (6 out of 16 patents)

14. Yinghui Sun (6 out of 9 patents)

15. Aiming Zhang (5 out of 13 patents)

33 patents: Sort by Forward Citations

1. 12097204 - Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof (2024-09-24),

2. 11773079 - Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine (2023-10-03),

3. 11254665 - Crystalline sulfamide compound (2022-02-22),

4. 11203586 - Iridinesulfonamide compound and use method thereof (2021-12-21),

5. 11111240 - Sultam compound and application method thereof (2021-09-07),

6. 11098060 - Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof (2021-08-24),

7. 11021464 - Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine methanesulfonic acid salt (2021-06-01),

8. 10858340 - Crystal of salt of quinazoline derivative (2020-12-08),

9. 10829492 - Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor (2020-11-10),

10. 10822319 - Crystal of DPP-IV long-acting inhibitor and salt (2020-11-03),

11. 10766901 - Preparation method for chiral pyrrolopyrimidine compound (2020-09-08),

12. 10745383 - 1,3,5-triazine derivative and method of using same (2020-08-18),

13. 10626118 - Pyrrolopyrimidine crystal for preparing JAK inhibitor (2020-04-21),

14. 10617692 - Pyrrolopyrimidine comprising cyclopentyl substituent (2020-04-14),

15. 10570141 - Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof (2020-02-25),

Centaurus Biopharma is a leading biotechnology company specializing in innovative drug development. With a focus on developing advanced therapies for various diseases, Centaurus aims to improve patient care and quality of life. The company is committed to delivering safe and effective treatments through rigorous research and development efforts. Visit our website to learn more about our pioneering solutions and ongoing projects.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

33 Patents

#113 in Beijing

#855 in China

#19,554 in the World

Centaurus Biopharma Co., Ltd.

Forward Citations = 53

105 inventors:

Yongxin Han (17 out of 21 patents)

Yong Peng (14 out of 26 patents)

Yuandong Hu (14 out of 15 patents)

4. Hong Luo (13 out of 17 patents)

5. Dengming Xiao (12 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…